NCT07114055View on ClinicalTrials.gov

Effect of Ebastine in Patients With Diarrhea Predominant Irritable Bowel Syndrome

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Irritable Bowel Syndrome - Diarrhoea
Interventions
DRUG

ebastine

Tab. Ebastine 20mg once daily at night

DRUG

Placebo

Tab. Placebo once daily at night

Trial Locations (1)

Unknown

RECRUITING

Dhaka Medical College, Dhaka

All Listed Sponsors
lead

Md. Hazrat Ali

OTHER

NCT07114055 - Effect of Ebastine in Patients With Diarrhea Predominant Irritable Bowel Syndrome | Biotech Hunter | Biotech Hunter